Alpha-1 Antitrypsin Deficiency Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, and Companies by DelveInsight
In September 2023, The US Food and Drug Administration has approved Krystal Biotech’s Investigational New Drug (IND) ...
KRRO stock touches 52-week low at $29.8 amid yearly slump
Frequency Therapeutics Inc (KRRO) stock has hit a 52-week low, trading at $29.8, marking a significant downturn for the company within the past year. According to InvestingPro data, the company ...
BMO Capital maintains Outperform on Beam Therapeutics stock
BMO Capital Markets reaffirmed their Outperform rating on Beam Therapeutics Inc (NASDAQ:BEAM), with a steady price target of $57.00. Currently trading at $26.57, the stock appears undervalued ...
pharmaphorum2d
Wave surges on first RNA editing data in humans
Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...
Healthline18d
COPD Tests and Diagnosis
People with low levels of AAT have a condition called alpha-1 antitrypsin deficiency and often develop COPD at a young age. Through genetic testing, you can find out whether you have an AAT ...
The Alpha-1 Foundation Commemorates its 30th Anniversary
The Alpha-1 Foundation (A1F) is proud to commemorate its 30th anniversary of supporting patients with Alpha-1 Antitrypsin ...
Rare genetic lung condition limits life for Manawatū mum of three
A rare lung condition has left the 41-year-old, who lives in Halcombe in the Manawatū district, relying on an oxygen tank to survive. Ten years ago, Carruthers’ life changed when the constant ...